Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
NCT03214172
·
clinicaltrials.gov ↗
COMPLETED
Status
1000
Enrollment
INDUSTRY
Sponsor class
Conditions
Venous Thromboembolism
Interventions
DRUG:
Rivaroxaban (Xarelto, BAY59-7939)
Sponsor
Bayer
Collaborators
[object Object]